伦诺克斯-加斯托综合征的当前和新兴药物治疗方法
1Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Expert opinion on pharmacotherapy
|June 5, 2025
概括
伦诺克斯-加斯托综合征 (LGS) 治疗仍然具有挑战性,需要个性化计划. 本综述涵盖了目前FDA批准的和新兴的治疗方法,用于这种严重的儿童脑病.
科学领域:
- 神经学 神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伦诺斯-加斯托综合征 (LGS) 是一种严重的儿童发作的性脑病变.
- 它的特点是抗药性和认知障碍,显著影响生活质量.
- 为LGS开发有效的药物疗法是一个关键的临床挑战.
研究的目的:
- 对伦诺克斯-加斯托综合征 (LGS) 的现有和新兴药物疗法进行审查.
- 讨论LGS管理中的治疗挑战和未来方向.
- 探索针对LGS病因的精密治疗方法.
主要方法:
- 对随机对照试验,观察性研究和专家共识陈述的综合文献综述.
- 对FDA批准的抗发作药物 (ASM) 对LGS的检查.
- 对非标签的ASM,试验性治疗方法和精密治疗方法的分析.
主要成果:
- 美国食品和药物管理局批准的药物包括克洛纳泽,费尔巴酸盐,拉莫特里金,托皮拉酸盐,鲁菲纳米德,克洛巴赞,大麻和芬拉胺.
- 大多数LGS患者缺乏个性化治疗计划,突出了当前管理中的差距.
- 新兴的精确疗法对遗传定义的LGS亚型有希望.
结论:
- 目前的LGS管理需要采用多式模式的方法,将药物治疗与其他干预措施相结合.
- 未来的进步需要改善自然历史研究,数据收集,临床前模型和创新的试验设计.
- 迫切需要优化现有的治疗方法和疾病修饰策略,以解决LGS的和非结局.
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
528
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
528
01:28Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
685
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
685
01:20Antiepileptic Drugs: Potassium Channel Activators
291
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
291
01:26Psychosis: Goals of Pharmacotherapy
216
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
216
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
463
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
463